4-aminobenzoic acid has been researched along with B-Cell Lymphoma in 1 studies
para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.
4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate whether the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) combined with the selective MDM2 antagonist idasanutlin (RG7388) offers superior efficacy to monotherapy in treating B-lymphoid malignancies in preclinical models." | 1.43 | Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388). ( Bacac, M; Dangl, M; Friess, T; Herter, S; Herting, F; Klein, C; Muth, G; Sulcova, J; Umana, P, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herting, F | 1 |
| Herter, S | 1 |
| Friess, T | 1 |
| Muth, G | 1 |
| Bacac, M | 1 |
| Sulcova, J | 1 |
| Umana, P | 1 |
| Dangl, M | 1 |
| Klein, C | 1 |
1 other study available for 4-aminobenzoic acid and B-Cell Lymphoma
| Article | Year |
|---|---|
Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxi | 2016 |